度洛西汀
安慰剂
中止
盐酸度洛西汀
文拉法辛
汉密尔顿焦虑量表
内科学
盐酸文拉法辛
广泛性焦虑症
耐受性
心理学
医学
焦虑
不利影响
麻醉
精神科
抗抑郁药
病理
替代医学
作者
James T. Hartford,Susan G. Kornstein,Michael R. Liebowitz,Teresa A. Pigott,James Russell,Michael J. Detke,Daniel J. Walker,Susan G. Ball,Eduardo Dunayevich,Jeff Dinkel,J. Erickson
标识
DOI:10.1097/yic.0b013e32807fb1b2
摘要
This study examined the efficacy and tolerability of duloxetine 60-120 mg/day for the treatment of patients with generalized anxiety disorder. This was a multicenter, randomized, double-blind, flexible-dose, placebo and active-controlled (venlafaxine extended-release 75-225 mg/day) trial designed to assess duloxetine 60-120 mg/day during 10 weeks of treatment in adults with Diagnostic and statistical manual of mental disorders-IV-defined generalized anxiety disorder. The primary efficacy outcome measure was mean change from baseline to endpoint in the Hamilton Anxiety Rating Scale total score assessed using analysis of covariance. A total of 487 patients were randomly assigned to duloxetine (n=162), venlafaxine XR (n=164), or placebo (n=161). Significantly greater improvement on the Hamilton Anxiety Rating Scale total score occurred in the duloxetine (P=0.007) and venlafaxine XR (P<0.001) groups compared with the placebo group. Overall discontinuation rates did not differ among the three groups, but adverse event-related discontinuation was significantly higher in the duloxetine (14.2%, P<0.001) and venlafaxine XR (11.0%, P=0.001) groups than in the placebo group (1.9%). During the 2-week drug-tapering phase, discontinuation-emergent adverse events were significantly greater in the venlafaxine XR group (26.9%, P=0.04), but not in the duloxetine group (19.4%, P=0.448) compared with placebo (15.8%). Duloxetine 60-120 mg/day and venlafaxine XR 75-225 mg/day were each efficacious treatments for patients with generalized anxiety disorder.
科研通智能强力驱动
Strongly Powered by AbleSci AI